Literature DB >> 28762374

Molecular alterations in prostate cancer and association with MRI features.

D Lee1, J Fontugne2,3, N Gumpeni4, K Park2, T Y MacDonald2,3,5, B D Robinson1,2,3,5, A Sboner1,3,5,6, M A Rubin1,2,3,5, J M Mosquera1,2,3,5, C E Barbieri1,2,5.   

Abstract

BACKGROUND: Multiparametric magnetic resonance imaging (mpMRI) has been increasingly used for prostate cancer (PCa). Recent studies identified distinct molecular subclasses of PCa with recurrent genomic alterations. However, the associations between molecular alterations in PCa and characteristics on mpMRI are unknown. Therefore, the objective of this study was to investigate recurrent molecular alterations in PCa and their associations with mpMRI features.
METHODS: Sixty-two PCa nodules >0.5 cm had a preoperative mpMRI. Nodules were evaluated for ERG rearrangement, PTEN deletion, SPINK1 overexpression, SPOP mutation and CHD1 deletion. Each PCa focus was matched to the corresponding location on mpMRI. Lesions were scored by single observer according to the PI-RADSv2 scale.
RESULTS: Of the 62 nodules, 22 (35.5%) were ERG positive, 6 (9.7%) had SPINK1 overexpression, 6 (9.7%) had SPOP mutations, 4 (6.5%) had CHD1 deletions and 1 (1.6%) had PTEN deletion. All of the nodules with CHD1 deletions were not visible on mpMRI (P=0.037). All of the nodules with SPINK1 overexpression were visible on mpMRI, although the association was not statistically significant (P=0.06). There were no significant associations between any molecular alteration with the severity of the PI-RADS scores (all P>0.05).
CONCLUSIONS: This investigation represents the first description of an association between recurrent molecular alterations and the characterization of PCa nodules on mpMRI. This study can be considered hypothesis-generating for future studies to rigorously evaluate the association of specific PCa molecular subclasses with imaging features and potentially define specific subsets of PCa for which the utility of MRI is higher or lower.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28762374     DOI: 10.1038/pcan.2017.33

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  30 in total

1.  Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.

Authors:  Stéphane Terry; Nathalie Nicolaiew; Victor Basset; Fannie Semprez; Pascale Soyeux; Pascale Maillé; Francis Vacherot; Guillaume Ploussard; Arturo Londoño-Vallejo; Alexandre de la Taille; Yves Allory
Journal:  Cancer       Date:  2015-01-13       Impact factor: 6.860

2.  ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer.

Authors:  Kasper Drimer Berg; Ben Vainer; Frederik Birkebæk Thomsen; M Andreas Røder; Thomas Alexander Gerds; Birgitte Grønkær Toft; Klaus Brasso; Peter Iversen
Journal:  Eur Urol       Date:  2014-03-07       Impact factor: 20.096

3.  Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.

Authors:  M Minhaj Siddiqui; Soroush Rais-Bahrami; Baris Turkbey; Arvin K George; Jason Rothwax; Nabeel Shakir; Chinonyerem Okoro; Dima Raskolnikov; Howard L Parnes; W Marston Linehan; Maria J Merino; Richard M Simon; Peter L Choyke; Bradford J Wood; Peter A Pinto
Journal:  JAMA       Date:  2015-01-27       Impact factor: 56.272

4.  Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins.

Authors:  Johan Lindberg; Daniel Klevebring; Wennuan Liu; Mårten Neiman; Jianfeng Xu; Peter Wiklund; Fredrik Wiklund; Ian G Mills; Lars Egevad; Henrik Grönberg
Journal:  Eur Urol       Date:  2012-03-31       Impact factor: 20.096

5.  A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis.

Authors:  Jacques Lapointe; Young H Kim; Melinda A Miller; Chunde Li; Gulsah Kaygusuz; Matt van de Rijn; David G Huntsman; James D Brooks; Jonathan R Pollack
Journal:  Mod Pathol       Date:  2007-03-02       Impact factor: 7.842

Review 6.  Updated trends in imaging use in men diagnosed with prostate cancer.

Authors:  S P Porten; A Smith; A Y Odisho; M S Litwin; C S Saigal; P R Carroll; M R Cooperberg
Journal:  Prostate Cancer Prostatic Dis       Date:  2014-05-13       Impact factor: 5.554

7.  Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.

Authors:  Maisa Yoshimoto; Anthony M Joshua; Isabela W Cunha; Renata A Coudry; Francisco P Fonseca; Olga Ludkovski; Maria Zielenska; Fernando A Soares; Jeremy A Squire
Journal:  Mod Pathol       Date:  2008-05-23       Impact factor: 7.842

Review 8.  Systematic, evidence-based discovery of biomarkers at the NCI.

Authors:  John R Prensner; Arul M Chinnaiyan; Sudhir Srivastava
Journal:  Clin Exp Metastasis       Date:  2012-08-07       Impact factor: 5.150

9.  TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.

Authors:  Sven Perner; Juan-Miguel Mosquera; Francesca Demichelis; Matthias D Hofer; Pamela L Paris; Jeff Simko; Colin Collins; Tarek A Bismar; Arul M Chinnaiyan; Angelo M De Marzo; Mark A Rubin
Journal:  Am J Surg Pathol       Date:  2007-06       Impact factor: 6.394

10.  The genomic complexity of primary human prostate cancer.

Authors:  Michael F Berger; Michael S Lawrence; Francesca Demichelis; Yotam Drier; Kristian Cibulskis; Andrey Y Sivachenko; Andrea Sboner; Raquel Esgueva; Dorothee Pflueger; Carrie Sougnez; Robert Onofrio; Scott L Carter; Kyung Park; Lukas Habegger; Lauren Ambrogio; Timothy Fennell; Melissa Parkin; Gordon Saksena; Douglas Voet; Alex H Ramos; Trevor J Pugh; Jane Wilkinson; Sheila Fisher; Wendy Winckler; Scott Mahan; Kristin Ardlie; Jennifer Baldwin; Jonathan W Simons; Naoki Kitabayashi; Theresa Y MacDonald; Philip W Kantoff; Lynda Chin; Stacey B Gabriel; Mark B Gerstein; Todd R Golub; Matthew Meyerson; Ashutosh Tewari; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway
Journal:  Nature       Date:  2011-02-10       Impact factor: 49.962

View more
  8 in total

1.  SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.

Authors:  Gunther Boysen; Daniel N Rodrigues; Pasquale Rescigno; George Seed; David Dolling; Ruth Riisnaes; Mateus Crespo; Zafeiris Zafeiriou; Semini Sumanasuriya; Diletta Bianchini; Joanne Hunt; Deirdre Moloney; Raquel Perez-Lopez; Nina Tunariu; Susana Miranda; Inês Figueiredo; Ana Ferreira; Rossitza Christova; Veronica Gil; Sara Aziz; Claudia Bertan; Flavia M de Oliveira; Mark Atkin; Matthew Clarke; Jane Goodall; Adam Sharp; Theresa MacDonald; Mark A Rubin; Wei Yuan; Christopher E Barbieri; Suzanne Carreira; Joaquin Mateo; Johann S de Bono
Journal:  Clin Cancer Res       Date:  2018-08-01       Impact factor: 12.531

2.  Biologic Significance of Magnetic Resonance Imaging Invisibility in Localized Prostate Cancer.

Authors:  Simpa S Salami; Jeremy B Kaplan; Srinivas Nallandhighal; Mandeep Takhar; Jeffrey J Tosoian; Matthew Lee; Junhee Yoon; Daniel H Hovelson; Komal R Plouffe; Samuel D Kaffenberger; Edward M Schaeffer; R Jeffrey Karnes; Tamara L Lotan; Todd M Morgan; Arvin K George; Jeffrey S Montgomery; Matthew S Davenport; Sungyong You; Scott A Tomlins; Nicole E Curci; Hyung L Kim; Daniel E Spratt; Aaron M Udager; Ganesh S Palapattu
Journal:  JCO Precis Oncol       Date:  2019-06-12

Review 3.  SPOP and cancer: a systematic review.

Authors:  Alison Clark; Marieke Burleson
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

4.  Prognostic Features of Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy Based on Multiparametric MRI and Immunohistochemistry Analysis of MRI-guided Biopsy Specimens.

Authors:  Stephanie A Harmon; William Gesztes; Denise Young; Sherif Mehralivand; Yolanda McKinney; Thomas Sanford; Jonathan Sackett; Jennifer Cullen; Inger L Rosner; Shiv Srivastava; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke; Albert Dobi; Isabell A Sesterhenn; Baris Turkbey
Journal:  Radiology       Date:  2021-04-13       Impact factor: 29.146

5.  Converging blockchain and next-generation artificial intelligence technologies to decentralize and accelerate biomedical research and healthcare.

Authors:  Polina Mamoshina; Lucy Ojomoko; Yury Yanovich; Alex Ostrovski; Alex Botezatu; Pavel Prikhodko; Eugene Izumchenko; Alexander Aliper; Konstantin Romantsov; Alexander Zhebrak; Iraneus Obioma Ogu; Alex Zhavoronkov
Journal:  Oncotarget       Date:  2017-11-09

6.  A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.

Authors:  Constantin Georgescu; Joshua M Corbin; Sandra Thibivilliers; Zachary D Webb; Yan D Zhao; Jan Koster; Kar-Ming Fung; Adam S Asch; Jonathan D Wren; Maria J Ruiz-Echevarría
Journal:  BMC Cancer       Date:  2019-05-06       Impact factor: 4.430

Review 7.  The diverse roles of SPOP in prostate cancer and kidney cancer.

Authors:  Zhiwei Wang; Yizuo Song; Miaomiao Ye; Xiaoming Dai; Xueqiong Zhu; Wenyi Wei
Journal:  Nat Rev Urol       Date:  2020-04-30       Impact factor: 14.432

Review 8.  Genetic Landscape of Prostate Cancer Conspicuity on Multiparametric Magnetic Resonance Imaging: A Systematic Review and Bioinformatic Analysis.

Authors:  Joseph M Norris; Benjamin S Simpson; Marina A Parry; Clare Allen; Rhys Ball; Alex Freeman; Daniel Kelly; Hyung L Kim; Alex Kirkham; Sungyong You; Veeru Kasivisvanathan; Hayley C Whitaker; Mark Emberton
Journal:  Eur Urol Open Sci       Date:  2020-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.